MedPath

Treatment of Resistant Depression by Repetitive Transcranial Magnetic Stimulation (rTMS) Multicentric Naturalistic Study

Not Applicable
Recruiting
Conditions
To Evaluate the Effectiveness of Open rTMS
Interventions
Device: rTMS basic
Device: rTMS SAINT
Device: rTMS VIIT
Device: rTMS SAINT modified
Registration Number
NCT04354935
Lead Sponsor
Centre hospitalier de Ville-Evrard, France
Brief Summary

Repetitive Transcranial Magnetic Stimulation (rTMS) for repetitive Transcranial Magnetic Stimulation) is a a recent technique to stimulate the brain in a way that non-invasive, for therapeutic purposes. The first trials of analgesic use of rTMS date back to about 15 years ago. years and clinical use has now entered the practice of some specialized centers. Used at a frequency less than or equal to 1 Hertz (Hz; a stimulation per second), it is called bass rTMS. frequency and results in inhibition of cortical excitability at the level of the stimulated area. Conversely, a stimulation with a frequency higher than 5 Hz, called high-frequency rTMS, will have an excitatory effect on the targeted neurons. In addition to its local effects at the stimulation site, rTMS can also have effects on distance on regions other than those directly targeted. The impact of this treatment would be the local modulation of the cerebral plasticity and also act on the anatomical connectivity and functional brain function in both healthy subjects and those who are patients with psychiatric disorders

Detailed Description

Main objective :

To show the effectiveness of rTMS carried out in open on the symptoms of depression resistant in common practice between the Baseline and the end of the initial treatment (between 1 and 6 weeks).

Secondary Objectives

Evaluate the tolerance of the rTMS carried out in open on the symptoms of depression resistant in common practice between the Baseline and the end of the initial cure (between 1 and 6 weeks)

Evaluate the impact of this treatment on :

* The response rate

* The remission rate

* Quality of life To assess the correlation between personality dimensions and depression.

The criteria main evaluation :

The evolution of the HDRS-17 score (Hamilton depression scale, 17 items) between the Baseline and the end of the initial treatment (1 to 6 weeks)

The evaluation criteria secondary :

* Responder patient rate (defined as a 50% decrease in the rate of

% of HDRS score)

* Rate of patients in remission (defined by HDRS score\<8)

* Evolution of the EQ5D quality of life score between Baseline and end of the initial treatment (between 1 and 6 weeks)

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
160
Inclusion Criteria
  • Presenting a depressive episode characterized as resistant according to the DSM 5 criteria
  • resistance is characterized by: non-response to at least two different antidepressants prescribed at effective doses for a duration greater than or equal to 6 weeks.
  • Patient who agrees to participate in the study and who has signed an informed consent.
  • Patient fluent in French
  • Affiliation to a social security scheme.
  • Women of childbearing age must be on contraception
Exclusion Criteria
  • Presenting a contraindication to TMS: intrafemale foreign body cranial, unstable epilepsy, cochlear implant, pacemaker, pregnancy
  • Presence of a psychotic disorder
  • Presence of an unstable medical condition
  • Presence of schizophrenia or persistent delusional disorder
  • Persons under guardianship, curatorship and safeguarding of justice.
  • Pregnant women,
  • Woman of childbearing age without effective contraception
  • Breastfeeding woman

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Method 3 (FDA)rTMS basictarget region: Dorsolateral Prefrontal left Fréquence : 10HZ Intensity of the stimulation : 120% SM duration : 37 minutes Number of pulses : 3000
Method 6 (SNT)rTMS SAINTTarget region: Dorsolateral Prefrontal left Fréquence : 50HZ Intensity of the stimulation : 90% SM Duration : 9 minutes Number of pulses : 1800
Method 1 ( iTBS)rTMS basictarget region: Dorsolateral Prefrontal left Fréquence : 50 Hz Intensity of the stimulation : 120% SM duration : 3 minutes Number of pulses : 600
Method 4 (ITBS VIIT)rTMS VIITtarget region: Dorsolateral Prefrontal left Fréquence : 50HZ Intensity of the stimulation : 90% SM Duration : 9 minutes Number of pulses : 1800
Method 7 (DASH)rTMS basicTarget region: Dorsolateral Prefrontal left Fréquence : 10HZ Intensity of the stimulation : 120% SM Duration : 18.75 minutes Number of pulses : 3000
Method 2 (French touch)rTMS basictarget region : dorsolateral prefrontal cortex right Frequency:1HZ Intensity:120% SM duration : 8 Min 30 Sec Number of plulses : 360
Method 5 (SNTm)rTMS SAINT modifiedTarget region: Dorsolateral Prefrontal left Fréquence : 50HZ Intensity of the stimulation : 90% SM Duration : 9 minutes Number of pulses : 1800
Primary Outcome Measures
NameTimeMethod
measure the evolution of the HDRS-17 scorean average of 1 year

The evolution of the HDRS-17 score (Hamilton depression scale, 17 items) between the Baseline and the end of the initial 4 to 6 week treatment course

Secondary Outcome Measures
NameTimeMethod
Rate of responding patientsan average of 1 year

Rate of responder patients (defined by a 50% decrease in HDRS score)

Evolution of the quality of life scorean average of 1 year

EQ5D between Baseline and the end of the initial treatment between 4 and 6 weeks

Rate of patients in remissionan average of 1 year

defined by HDRS score\<8

Trial Locations

Locations (2)

Youcef Bencherif

🇫🇷

Neuilly sur Marne, France

Unité de recherche clinique

🇫🇷

Neuilly Sur Marne, Île De France, France

© Copyright 2025. All Rights Reserved by MedPath